We are Inhibikase Therapeutics, a pharmaceutical company innovating small-molecule kinase inhibitor therapeutics to treat Parkinson’s disease, Parkinson’s-related neurodegenerative …

2 days ago · Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and abandoned assets in recent months.

2 days ago · Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.

4 days ago · Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out …

2 days ago · Inhibikase is pausing work on its experimental Parkinson’s drug risvodetinib and seeking options after it came up short in the efficacy stakes.

We have developed a platform prodrug technology that adds a small linker to a known or novel kinase inhibitor and suppresses on-dosing side effects common to drugs in this class, …

Inhibikase Therapeutics develops treatments that seek to intervene in neurodegeneration where disease begins. Our treatments flow from a novel understanding of the etiology—cause or set …

Mar 20, 2024 · At the 2024 AD/PD Meeting, held March 5-9, in Lisbon, Portugal, Inhibikase presented an update on its phase 2 study, Trial 201 (NCT05424276), assessing its …

May 16, 2023 · Inhibikase's multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the …

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a...